<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Scienture Holdings, Inc. — News on 6ix</title>
<link>https://6ix.com/company/scienture-holdings-inc</link>
<description>Latest news and press releases for Scienture Holdings, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 15 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/scienture-holdings-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835bdc178dffbe2df117575.webp</url>
<title>Scienture Holdings, Inc.</title>
<link>https://6ix.com/company/scienture-holdings-inc</link>
</image>
<item>
<title>Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-price-requirement</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-price-requirement</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>COMMACK, NY, April 15, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”) a holding company for existing and planned</description>
</item>
<item>
<title>Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-provides-annual-shareholder-update-outlining-significant-progress-and-strategic-priorities-for-the-year-ahead</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-provides-annual-shareholder-update-outlining-significant-progress-and-strategic-priorities-for-the-year-ahead</guid>
<pubDate>Mon, 06 Apr 2026 04:00:00 GMT</pubDate>
<description>COMMACK, NY, April 06, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”) a holding company for existing and planned</description>
</item>
<item>
<title>SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-reports-year-end-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-reports-year-end-2025-financial-results-and-provides-business-update</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Reports Significant Revenue Growth and Gross Margin Expansion in 2025 COMMACK, NY, March 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX)</description>
</item>
<item>
<title>SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-broadens-commercial-access-for-rezenopytm-highest-dose-fda-approved-naloxone-nasal-spray-through-gpo-agreements-reaching-over-5000-us-institutions</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-broadens-commercial-access-for-rezenopytm-highest-dose-fda-approved-naloxone-nasal-spray-through-gpo-agreements-reaching-over-5000-us-institutions</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>Expands institutional footprint with potential penetration of more than ~ 60% of the U.S. market, while expanding reach across EMS providers and</description>
</item>
<item>
<title>SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-provides-commercial-arbli-first-130500698</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-provides-commercial-arbli-first-130500698</guid>
<pubDate>Tue, 03 Feb 2026 13:05:00 GMT</pubDate>
<description>Company highlights accelerating access and revenue growth for ARBLI™ and confirms REZENOPY™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million Outlines Q1 2026 outlook and reports significant balance sheet improvement last quarter COMMACK, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patient</description>
</item>
<item>
<title>SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-announces-issuance-orange-book-130500882</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-announces-issuance-orange-book-130500882</guid>
<pubDate>Wed, 14 Jan 2026 13:05:00 GMT</pubDate>
<description>U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that the United States Patent and Trad</description>
</item>
<item>
<title>SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-provides-commercial-launch-rezenopy-130500874</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-provides-commercial-launch-rezenopy-130500874</guid>
<pubDate>Mon, 22 Dec 2025 13:05:00 GMT</pubDate>
<description>U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided an update on the commercial launch of R</description>
</item>
<item>
<title>SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-blinkrx-announce-strategic-collaboration-130500470</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-blinkrx-announce-strategic-collaboration-130500470</guid>
<pubDate>Wed, 10 Dec 2025 13:05:00 GMT</pubDate>
<description>U.S. Losartan market totals $245M annually with 71M prescriptions COMMACK, NY, Dec. 10, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, and Blink Rx LLC (“BlinkRx”), one of the most advanced patient access p</description>
</item>
<item>
<title>SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-participate-iaccess-alpha-virtual-130500043</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-participate-iaccess-alpha-virtual-130500043</guid>
<pubDate>Tue, 02 Dec 2025 13:05:00 GMT</pubDate>
<description>COMMACK, NY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that management will be participating in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on Decemb</description>
</item>
<item>
<title>SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-reports-q3-2025-financial-130500598</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-reports-q3-2025-financial-130500598</guid>
<pubDate>Thu, 13 Nov 2025 13:05:00 GMT</pubDate>
<description>Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K Launched Sales of Arbli™, the First FDA-Approved Ready-To-Use Liquid Formulation of Losartan for Hypertension COMMACK, NY, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distrib</description>
</item>
<item>
<title>SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-announces-addition-arbli-losartan-130500649</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-announces-addition-arbli-losartan-130500649</guid>
<pubDate>Tue, 04 Nov 2025 13:05:00 GMT</pubDate>
<description>Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that Arbli™ (losartan potassium) Oral Suspension, 10</description>
</item>
<item>
<title>SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-announces-start-commercial-sales-120500876</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-announces-start-commercial-sales-120500876</guid>
<pubDate>Thu, 23 Oct 2025 12:05:00 GMT</pubDate>
<description>Company launches multi-channel promotional campaign to drive market adoption U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the de</description>
</item>
<item>
<title>SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-arbli-becomes-first-fda-130000756</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-arbli-becomes-first-fda-130000756</guid>
<pubDate>Thu, 16 Oct 2025 13:00:00 GMT</pubDate>
<description>Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to swallow tablets U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to</description>
</item>
<item>
<title>SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-holdings-announces-full-repayment-130000600</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-holdings-announces-full-repayment-130000600</guid>
<pubDate>Wed, 08 Oct 2025 13:00:00 GMT</pubDate>
<description>COMMACK, NY, Oct. 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that on October 3, 2025, it entered into an agreement (the “Agreement”) with Arena Finance Markets, LP and Arena Special</description>
</item>
<item>
<title>SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-secures-multiple-commercial-gpo-130000928</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-secures-multiple-commercial-gpo-130000928</guid>
<pubDate>Wed, 01 Oct 2025 13:00:00 GMT</pubDate>
<description>Represents potential penetration into ~ 20% of the U.S. institutional market, while broadening access across long-term care and outpatient facilities U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on provi</description>
</item>
<item>
<title>SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-secures-pbm-led-gpo-120500477</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-secures-pbm-led-gpo-120500477</guid>
<pubDate>Tue, 16 Sep 2025 12:05:00 GMT</pubDate>
<description>Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing volume and extended room-temperature shelf life COMMACK, NY, Sept. 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel</description>
</item>
<item>
<title>Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-holdings-inc-announces-pricing-130000731</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-holdings-inc-announces-pricing-130000731</guid>
<pubDate>Thu, 14 Aug 2025 13:00:00 GMT</pubDate>
<description>Commack, NY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Scienture Holdings, Inc. (Nasdaq: SCNX) (“Scienture” or the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that it has entered into a securities purchase agreement with certain institutional investors to pu</description>
</item>
<item>
<title>SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-announces-shipment-launch-quantities-120500944</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-announces-shipment-launch-quantities-120500944</guid>
<pubDate>Wed, 13 Aug 2025 12:05:00 GMT</pubDate>
<description>COMMACK, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the shipment of launch quantities of Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL to its 3PL/Distribution Center fo</description>
</item>
<item>
<title>Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-holdings-inc-obtains-1-211200699</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-holdings-inc-obtains-1-211200699</guid>
<pubDate>Thu, 24 Jul 2025 21:12:00 GMT</pubDate>
<description>Commack, NY, July 24, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that its board of directors has approved a bridge funding raise of up to an aggregate amount of $3 million, of whic</description>
</item>
<item>
<title>Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements</title>
<link>https://6ix.com/company/scienture-holdings-inc/news/scienture-holdings-inc-regains-compliance-121500984</link>
<guid isPermaLink="true">https://6ix.com/company/scienture-holdings-inc/news/scienture-holdings-inc-regains-compliance-121500984</guid>
<pubDate>Wed, 16 Jul 2025 12:15:00 GMT</pubDate>
<description>Commack, NY, July 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that it has received a notification letter from The Nasdaq Stock Market (“Nasdaq”) stating that the Company has reg</description>
</item>
</channel>
</rss>